A recent study reveals that individuals who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop conventional diet and exercise plans.
Published data in a leading medical journal points out that while overweight individuals frequently drop about a fifth of their total mass while using the jabs, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Individuals buying these medications must be aware of the danger of quick rebound weight gain when the medication is stopped," cautioned researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to original weight within about one and a half years.
Analyzing Approaches
The research, which examined 37 of trials involving thousands of participants, compared the results of GLP-1 agonists with older methods.
Researchers note that people who lose weight through dieting usually have a less rapid creep back—approximately 0.1 kg a month—after stopping.
Understanding the Rapid Regain
Doctors suggest the way of the injections accounts for the heightened regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate appetite.
"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the system to produce less of its own natural GLP-1, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Stopping of this medication results in hunger is unsuppressed, making excessive eating much more probable."
A Lifelong Issue?
The NHS suggest the jabs for people with weight-linked health risks, accompanied by recommended lifestyle changes.
Many experts contend that, given the likelihood of relapse, the treatment might need to be long-term.
This opinion is reinforced by pharmaceutical companies, who state that the results "highlight the chronic nature of obesity," similar to managing conditions like diabetes.
User Experiences
People who have discontinued the jabs describe a intense resurgence of hunger.
"I experienced a switch flipping and you're instantly starving," recalled a patient.
The struggle is worsened if patients have not developed permanent lifestyle or habit modifications during treatment.
Growing Use
Figures suggest that millions of adults in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Use is more common among women compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
Ultimately, clinicians caution that while the jabs are potent agents for shedding pounds, they are not a permanent fix and maintained weight loss hinges on combined lifestyle management.